Streetbeat News

Products Services

RARE

Ultragenyx Pharmaceutical (NASDAQ:RARE) has been evaluated by four analysts in the past three months, with all four maintaining a 'Somewhat Bullish' stance. The average 12-month price target for RARE is now $100.0, down 11.11% from the previous average, with a high estimate of $130.00 and a low of $72.00. Analysts from Cantor Fitzgerald, Wells Fargo, Morgan Stanley, and Piper Sandler have provided ratings and adjusted price targets, reflecting their views on the company's market position and financial performance. Ultragenyx Pharmaceutical is a biopharmaceutical company focusing on rare and ultra-rare diseases, with products like Crysvita, Dojolvi, and Mepsevii. Financially, the company has a high market capitalization and a positive revenue growth rate of 8.1%, but faces challenges with a net margin of -162.82%, ROE of -198.64%, ROA of -12.52%, and a high debt-to-equity ratio of 1.47.

Portfolio Pulse from Benzinga Insights

January 19, 2024 | 3:00 pm

AMGN

The FDA has mandated a boxed warning for Prolia, an osteoporosis medication, due to the increased risk of severe hypocalcemia in patients with advanced chronic kidney disease. This new warning is intended to alert healthcare professionals and patients about the potential risks associated with the drug's use in this particular population.

Portfolio Pulse from Benzinga Newsdesk

January 19, 2024 | 2:52 pm

AMD

HPE

ISRG

JNPR

META

NVDA

PANW

AI stocks have been leading gains in the S&P 500 index in January, with Juniper Networks, Nvidia, and Palo Alto Networks among the top performers. Juniper Networks received a $14 billion takeover offer from Hewlett Packard Enterprise, Nvidia continued its strong performance with a 15% gain in January, and Palo Alto Networks saw a 14% increase. Nvidia's technology and market share in AI GPUs, including a large purchase by Meta Platforms, positions it well for 2024. Palo Alto Networks is also favored by analysts for its role in cybersecurity against AI-powered threats. Other notable companies include AMD with a 10.3% gain and Intuitive Surgical, also up by 10.3%, both benefiting from the AI trend.

Portfolio Pulse from Neil Dennis

January 19, 2024 | 2:37 pm

MULN

Mullen Automotive has announced that Bollinger Motors, which it owns, has received orders for 40 B4, Class 4 electric trucks. The orders are valued at approximately $6 million.

Portfolio Pulse from Benzinga Newsdesk

January 19, 2024 | 2:31 pm

AIHS

Senmiao Technology Limited (NASDAQ:AIHS) has signed a strategic cooperation agreement with Anhui Lianma Technology to enhance its online ride-hailing platform operations in China. Lianma will manage the comprehensive operation of Senmiao's services in cities like Chengdu, Changsha, and Guangzhou, focusing on business development, resource management, and customer service. Senmiao expects this partnership to increase monthly completed orders and improve operational efficiency, countering recent challenges from competition and compliance checks by Gaode.

Portfolio Pulse from Benzinga Newsdesk

January 19, 2024 | 2:03 pm

DTSS

Datasea Inc. (NASDAQ:DTSS) has signed an agreement with Meglio Interiors LLC to promote and market its intelligent acoustics products in the U.S. This partnership aims to expand DTSS' presence in the U.S. market and is expected to boost product sales. Datasea plans to set up an assembly line in the U.S. and sees Meglio as a key distributor. The agreement, which has an initial term of two years, leverages Meglio's expertise in sales and marketing within the U.S. furniture market, deemed compatible with Datasea's home health products.

Portfolio Pulse from Benzinga Newsdesk

January 19, 2024 | 2:02 pm

CCHWF

HERTF

TCNNF

VRNOF

West Virginia Delegate Evan Hansen introduced House Bill 4873 to legalize recreational cannabis for adults over 21. The bill follows a similar unsuccessful attempt with House Bill 2091 and comes amid suggestions by Senate President Craig Blair to use marijuana legalization as a strategy against the state's fentanyl crisis. The bill proposes a 15% excise tax and a local 6% tax to fund county and municipal needs. Multi-state medical marijuana operators like Trulieve Cannabis Corp., Columbia Care Inc., Heritage Cannabis Holding Corp, and Verano Holdings could benefit if the bill passes.

Portfolio Pulse from Nina Zdinjak

January 19, 2024 | 1:56 pm

SMCI

Supermicro (NASDAQ:SMCI) has updated its Q2 fiscal 2024 guidance, raising EPS from $4.40-$4.88 to $5.40-$5.55 and net sales from $2.7B-$2.9B to $3.6B-$3.65B, surpassing estimates. The preliminary results reflect strong demand for their AI, Cloud, Storage, and 5G/Edge solutions. Final results may differ as they are subject to financial closing procedures. A conference call to review Q2 results is scheduled for January 29, 2024.

Portfolio Pulse from Benzinga Newsdesk

January 19, 2024 | 1:37 pm

IDAI

Trust Stamp (NASDAQ:IDAI) announced the USPTO issued a notice of allowance for its patent application on liveness-verified, biometric-based encryption. This technology aims to combat the rise in presentation attacks and is seen as essential in the context of increasing AI-powered threats, as highlighted by JPMorgan's report of 45 billion daily infiltration attempts.

Portfolio Pulse from Benzinga Newsdesk

January 19, 2024 | 1:32 pm

VXRT

Vaxart, Inc. has been awarded a $9.27 million BARDA Project NextGen award to prepare for a Phase 2b clinical study of its oral pill XBB COVID-19 vaccine candidate. The study will compare the vaccine to an approved mRNA vaccine. The funding is part of a $5 billion HHS initiative to develop vaccines offering broader, more durable protection against COVID-19. Vaxart's vaccine aims to address needle-phobia and provide a cross-reactive response to various COVID variants by triggering both systemic and mucosal immune responses.

Portfolio Pulse from Benzinga Newsdesk

January 19, 2024 | 1:31 pm